Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.80 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.77 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.67 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14793212 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL8738898 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14793208 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15386588 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15120601 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL12236914 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL12648548 | 1.00 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL15386586 | 0.99 | FABP3 (0.78) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL19821350 | 0.95 | FABP3 (0.80) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL17232172 | 0.95 | LPAR3 (0.85) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11786607-B2 | RNA formulations | MODERNATX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | MODERNATX, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-9901616-B2 | Apoptosis-targeting nanoparticles | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170189362-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9568454-B2 | Methods of separating lipids | WATERS TECHNOLOGIES CORPORATION (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORP (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University of Georgia Foundation, Inc. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University of Georgia Foundation, Inc. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120015023-A1 | Treatment of tumors prostate with arsonoliposomes | CELLVAX S.A. (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | AIFM1, BAX, BCL2 | FABP3 1651/4885LPAR3 2771/4885LPAR1 3100/4885 |
| US-10000447-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | FABP3 57/4885LPAR3 197/4885LPAR1 74/4885 |
| US-11786607-B2 | RNA formulations | SYNCRIP, NSUN3, RNMT | FABP3 68/4885LPAR3 156/4885LPAR1 204/4885 |
| US-20230330260-A1 | RNA FORMULATIONS | SYNCRIP, NSUN3, RNMT | FABP3 68/4885LPAR3 156/4885LPAR1 204/4885 |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | CFTR, SLC47A1, TMEM205 | FABP3 363/4885LPAR3 31/4885LPAR1 71/4885 |
| US-20170001950-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | FABP3 57/4885LPAR3 197/4885LPAR1 74/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | FABP3 407/4885LPAR3 408/4885LPAR1 511/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | FABP3 197/4885LPAR3 81/4885LPAR1 239/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | FABP3 18/4885LPAR3 270/4885LPAR1 305/4885 |
| US-20120015023-A1 | Treatment of tumors prostate with arsonoliposomes | ACP3, BPHL, AR | FABP3 1179/4885LPAR3 40/4885LPAR1 36/4885 |
| US-20170189362-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | FABP3 287/4885LPAR3 1037/4885LPAR1 743/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | FABP3 18/4885LPAR3 270/4885LPAR1 305/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | FABP3 561/4885LPAR3 1827/4885LPAR1 1122/4885 |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | GBA1, GAA, GLA | FABP3 198/4885LPAR3 87/4885LPAR1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.